Figure 4.

Pharmacologic Effects of Cardiac Myosin Inhibitors on the Pathomechanism of Obstructive Hypertrophic Cardiomyopathy

This novel drug class selectively and reversibly binds the allosteric binding site of the cardiac myosin ATPase, leading to a decrease in excessive myosin ATPase activity, which causes pathologic hypercontractility in HCM. Hence, in a downstream of events, causes a decrease in LVOT obstruction as well as diastolic dysfunction by mitigating the impaired LV relaxation in HCM. HCM = hypertrophic cardiomyopathy; LV = left ventricle; LVOT = left ventricular outflow tract.